Renal Outcomes in People With HIV-1 and Renal Impairment Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide: Integrated Analysis From 9 Phase 3/3b Clinical Trials

Open Forum Infectious Diseases 2026 Open access

Read full text
Authors: Frank A Post, David A. Wohl, Geoffroy Liegeon, Indira Brar, Debbie Hagins, Yazdan Yazdanpanah, Anchalee Avihingsanon, Hui Liu, Keith Aizen, Jason T. Hindman, Samir Gupta
DOI: 10.1093/ofid/ofag265
Cited by: 1
References: 16

Abstract

Among 1069 people with HIV-1 and mild to moderate renal impairment at baseline treated with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) across 9 clinical trials, renal function remained generally stable over follow-up of up to 240 weeks. Renal adverse events were infrequent, and discontinuation due to renal toxicity was rare.

Fields of Study & Subjects

HIV/AIDS drug development and treatment HIV-related health complications and treatments HIV Research and Treatment

Publication details

Journal / source
Open Forum Infectious Diseases
Publisher
Oxford University Press (OUP)
Volume
13
Issue
5
Pages
ofag265–ofag265
Publication date
28 April 2026
Language
EN